Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Heidi Hagen
AddedMar 31, 2024
UpdatedMay 31, 2026
Heidi Hagen

Heidi Hagen

Board Member, Vericel

CrunchbaseLinkedIn

Heidi Hagen's Career

Vericel
Vericel

Cambridge, MA, US

Board Member· Board
Obsidian Therapeutics
Obsidian Therapeutics

Cambridge, MA, US

Board Member· Board
Vineti
Vineti

San Francisco, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Heidi Hagen's Career

Vericel
Vericel
Public3051989Cambridge, MA, US
Board Member· Board

Leadership at Vericel

Paul WottonPaul WottonBoard Member
Nick ColangeloNick ColangeloBoard Member
Kevin McLaughlinKevin McLaughlinBoard Member
Robert ZerbeRobert ZerbeBoard Member

Similar to Vericel

CelularityCelularityFlorham Park, NJ, USCell Therapiesest. 2016CelularityFlorham Park, NJ, US · est. 2016

Celularity, a US-based biotech firm, pioneers in delivering large-scale, quality allogeneic placenta-derived cellular therapies.

Public · $400M225
Stemedica Cell TechnologiesStemedica Cell TechnologiesSan Diego, CA, USCell Therapy, Therapeuticsest. 2005Stemedica Cell TechnologiesSan Diego, CA, US · est. 2005

Stemedica Cell Technologies: Developing and commercializing cell and protein therapies for medical needs.

Series B · $67M175
Obsidian Therapeutics
Obsidian Therapeutics
Series B$164.5M902015Cambridge, MA, US
Board Member· Board

Leadership at Obsidian Therapeutics

Tariq KassumTariq KassumCo-Founder
Steve ShamahSteve ShamahCo-Founder
Madan JagasiaMadan JagasiaCEO
Anders GötzscheAnders GötzscheBoard Member
Michael GladstoneMichael GladstoneBoard Member
Michael GilmanMichael GilmanBoard Member

Similar to Obsidian Therapeutics

Odyssey TherapeuticsOdyssey TherapeuticsCambridge, MA, USPrecision Medicine, Therapeuticsest. 2021Odyssey TherapeuticsCambridge, MA, US · est. 2021

Odyssey Therapeutics: Innovating rapid, groundbreaking solutions in precision oncology and inflammation medicine.

Series C · $487M175
Cell BioEnginesCell BioEnginesNew York City, NY, USCell Therapiesest. 2022Cell BioEnginesNew York City, NY, US · est. 2022

Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.

Pre-Seed · $625k6
Black Diamond TherapeuticsBlack Diamond TherapeuticsCambridge, MA, USCancer Drugsest. 2017Black Diamond TherapeuticsCambridge, MA, US · est. 2017

Black Diamond Therapeutics, a US-based biotech firm, develops precision medicines for genetically-defined cancers.

Public · $272.1M65
OmniCyteOmniCyteBranford, CT, USCancer Treatmentest. 2012OmniCyteBranford, CT, US · est. 2012

Omnicyte: Innovating targeted cancer therapies via proprietary Immuno-Oncology Platform Technology.

Angel · $366k7
Vineti
Vineti
Series C$115.3M3752016San Francisco, CA, US
Co-Founder

Recent news

a16z-backed Rooms.xyz lets you build interactive, 3D rooms and simple games in your browserTechCrunch · 2023

Leadership at Vineti

Eli CasdinEli CasdinBoard Member
Stephen TingStephen TingCo-Founder
Emily MeltonEmily MeltonBoard Member
Amy DurossAmy DurossCo-Founder
Nina KjellsonNina KjellsonBoard Member
Ann KleinAnn KleinCEO

Similar to Vineti

Vita TherapeuticsVita TherapeuticsBaltimore, MD, USCell Therapiesest. 2018Vita TherapeuticsBaltimore, MD, US · est. 2018

Vita Therapeutics: Pioneering life-transformative treatments through cell engineering.

Series B · $63M33
ViTToria BiotherapeuticsViTToria BiotherapeuticsPhiladelphia, PA, USCell Therapiesest. 2021ViTToria BiotherapeuticsPhiladelphia, PA, US · est. 2021

Vittoria Biotherapeutics pioneers in gene-edited T-cell therapies, enhancing efficacy and safety in cell-based treatments.

Series B · $25M34
VintaBioVintaBioPhiladelphia, PA, USViral Vectorsest. 2020VintaBioPhiladelphia, PA, US · est. 2020

VintaBio: Expert CDMO provider for viral vectors, advancing cell and gene therapy manufacturing.

Series D · $64M15
Endpoint HealthEndpoint HealthPalo Alto, CA, USTests, Therapeuticsest. 2018Endpoint HealthPalo Alto, CA, US · est. 2018

Endpoint Health: Personalized therapies for immune-driven illnesses, improving patient outcomes.

Series D · $64.2M

Heidi Hagen's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Heidi Hagen

Anthony ShuberAnthony ShuberFounder · Exact SciencesAnita DavidsonAnita DavidsonCo-Founder · Creative BioTherapeuticsMark TegenMark TegenFounder · Inventure ChemicalsMike GiardelloMike GiardelloCo-Founder · Mount Wilson VenturesEvan WagnerEvan WagnerCo-Founder · SymbiontGlenn StarkmanGlenn StarkmanCo-Founder · Soteria